share_log

AbbVie | PRE 14A: Preliminary proxy statements relating to merger or acquisition

SEC announcement ·  Mar 4 17:25
Summary by Moomoo AI
AbbVie Inc. (AbbVie) has announced the upcoming 2024 Annual Meeting of Stockholders scheduled for May 3, 2024. The meeting will be held virtually, allowing stockholders to attend, vote, and submit questions online. The agenda includes the election of five directors to serve until the 2027 Annual Meeting, the ratification of Ernst & Young LLP as AbbVie's independent registered public accounting firm for 2024, advisory votes on executive compensation and the frequency of future stockholder advisory votes on executive compensation, and a management proposal to eliminate supermajority voting requirements. Additionally, three stockholder proposals will be considered if properly presented. The board recommends voting for the ratification of Ernst & Young LLP, for the approval of named executive officers' compensation, for annual advisory approvals of executive compensation, for the management proposal to eliminate supermajority voting, and against each of the stockholder proposals. The meeting will also address any other matters that may properly come before the meeting.
AbbVie Inc. (AbbVie) has announced the upcoming 2024 Annual Meeting of Stockholders scheduled for May 3, 2024. The meeting will be held virtually, allowing stockholders to attend, vote, and submit questions online. The agenda includes the election of five directors to serve until the 2027 Annual Meeting, the ratification of Ernst & Young LLP as AbbVie's independent registered public accounting firm for 2024, advisory votes on executive compensation and the frequency of future stockholder advisory votes on executive compensation, and a management proposal to eliminate supermajority voting requirements. Additionally, three stockholder proposals will be considered if properly presented. The board recommends voting for the ratification of Ernst & Young LLP, for the approval of named executive officers' compensation, for annual advisory approvals of executive compensation, for the management proposal to eliminate supermajority voting, and against each of the stockholder proposals. The meeting will also address any other matters that may properly come before the meeting.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more